Moderna stock surges as FDA reverses course, agrees to review new flu shot
Strong Bullish
100.0
Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
